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http://dx.doi.org/10.1016/j.ccell.2014.10.018SUMMARYTumors constitute highly suppressive microenvironments in which infiltrating T cells are ‘‘exhausted’’ by
inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits anti-
tumor and other CD8+ T cell-dependent chronic immune responses. TIGIT is highly expressed on human and
murine tumor-infiltrating T cells, and, in models of both cancer and chronic viral infection, antibody coblock-
ade of TIGIT and PD-L1 synergistically and specifically enhanced CD8+ T cell effector function, resulting in
significant tumor and viral clearance, respectively. This effect was abrogated by blockade of TIGIT’s comple-
mentary costimulatory receptor, CD226, whose dimerization is disrupted upon direct interaction with TIGIT in
cis. These results define a key role for TIGIT in inhibiting chronic CD8+ T cell-dependent responses.INTRODUCTION
Endogenous immune responses are often unable to reject tu-
mors, and strategies to elicit de novo antitumor responses by
vaccination have so far evinced relatively limited therapeutic
efficacy (Chen and Mellman, 2013; Kalos and June, 2013; Pal-
ucka and Banchereau, 2013; van den Boorn and Hartmann,
2013). These limitations are likely due to the immunosuppressive
nature of tumor microenvironments in which infiltrating tumor-
specific T cells become ‘‘exhausted’’ or otherwise suppressed
so that proliferative capacity and effector function are severely
impaired (Crespo et al., 2013, Schietinger and Greenberg,
2014). Recent efforts to reactivate immune responses by antag-
onizing the inhibitory signals utilized by tumors have shown
promise, with antibody blockade of T cell coinhibitory receptors
such as programmed death 1 (PD-1)/PD-L1 or cytotoxicSignificance
Strategies to reactivate exhausted antitumor immune response
such as PD-1/PD-L1 or CTLA-4 have demonstrated transform
multiple coinhibitory receptors on chronically activated T cells
modulate antitumor and other chronic immune responses. H
potently limit the effector function of chronically stimulated C
which TIGIT disrupts the homodimerization and function of its c
expand the scope of TIGIT’s role in immune responses and id
CaT-lymphocyte antigen 4 (CTLA-4) achieving response rates of
up to 50% in bladder, lung, and renal cancers and melanoma
(Chen and Mellman, 2013; Powles et al., 2014, J. Clin. Oncol.,
abstract). These results have generated substantial interest in
identifying additional inhibitory receptors that are expressed by
T cells in tumor microenvironments and that may contribute to
the suppression of cancer immunosurveillance.
T cell coinhibitory receptors were first identified by their re-
straint of autoimmunity inmice (Krummel and Allison, 1995; Nish-
imura et al., 1999; Tivol et al., 1995) and have subsequently been
found to be critical regulators of T cell exhaustion in the context of
chronic viral infections (Wherry, 2011). Mice acutely infectedwith
the Armstrong strain of lymphocytic choriomeningitis virus
(LCMV) mount a robust immune response that rapidly clears
the infection. In contrast, the use of the Clone 13 strain of
LCMV results in a chronic infection, eliciting the progressives with antibody blockade of key T cell coinhibitory receptors
ational potential in the clinic. However, the coexpression of
suggests that many inhibitory pathways may synergistically
ere we report that TIGIT collaborates with PD-1/PD-L1 to
D8+ T cells. We also characterize a mechanism of action in
omplementary costimulatory receptor, CD226. These results
entify TIGIT as a potential target for tumor immunotherapy.
ncer Cell 26, 923–937, December 8, 2014 ª2014 Elsevier Inc. 923
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TIGIT Limits Antitumor CD8+ T Cell Responsesexhaustion of effector CD8+ T cells, particularly in the absence of
adequate CD4+ T cell help (Ahmed et al., 1984; Gallimore et al.,
1998; Sullivan et al., 2011; Zajac et al., 1998). PD-1 is a central
regulator of this process, and antibody blockade of PD-1/PD-
L1 can partially restore antiviral T cell responses and enhance
viral clearance (Barber et al., 2006). Subsequent studies revealed
that these so-called exhausted CD8+ T cells expressmultiple co-
inhibitory receptors, including PD-1, CTLA-4, LAG-3, and TIM-3,
that converge to keep chronically activated effector T cells in
check (Wherry et al., 2007). These receptors can function syner-
gistically, particularly with PD-1, suggesting that individual
coinhibitory receptors contribute distinct functions to collectively
limit T cell responses (Blackburn et al., 2009; Curran et al., 2010;
Nakamoto et al., 2009). Moreover, tumor-infiltrating T cells
resemble exhausted antiviral T cells in their expression of many
of the same coinhibitory receptors, which, when inhibited, can
reactivate antiviral responses (Mellman et al., 2011).
To more fully assess the array of immune-modulatory recep-
tors on tumor-infiltrating lymphocytes, we interrogated human
tumor samples using immune cell-specific gene sets. The
T cell coinhibitory receptor TIGIT (T cell immunoglobulin and im-
munoreceptor tyrosine-based inhibitory motif [ITIM] domain)
was identified as consistently highly expressed across multiple
solid tumor types. TIGIT is an immunoglobulin superfamily mem-
ber expressed on subsets of activated T cells and natural killer
(NK) cells (Yu et al., 2009), although its role in CD8+ T cells is un-
known. Genetic ablation or antibody blockade of TIGIT has been
shown to enhance NK cell killing and CD4+ T cell priming in vitro
and in vivo and can exacerbate the severity of CD4+ T cell-
dependent autoimmune diseases such as experimental autoim-
mune encephalitis (Goding et al., 2013; Joller et al., 2011; Levin
et al., 2011; Lozano et al., 2012; Stanietsky et al., 2009, 2013;
Stengel et al., 2012; Yu et al., 2009). Conversely, administration
of TIGIT-Fc fusion proteins or agonistic anti-TIGIT antibodies
suppressed T cell activation in vitro and CD4+ T cell-dependent
delayed-type hypersensitivity in vivo (Yu et al., 2009). Coinhibi-
tory receptors can suppress immune responses by direct
signaling in cis, by inducing ligand signaling in trans, and by indi-
rect competition with complementary costimulatory receptors
(Chen and Flies, 2013). In the case of TIGIT, ligation of its high-
affinity cognate receptor, poliovirus receptor (PVR) (Stengel
et al., 2012), induces dendritic cells to acquire a tolerogenic
phenotype characterized by increased expression of IL-10 and
decreased expression of IL-12 (Yu et al., 2009). PVR also inter-
acts with CD226 (DNAM-1), the costimulatory counterreceptor
to TIGIT, but at a lower affinity. Analogous to the complementary
costimulatory and coinhibitory receptor pair CD28 and CTLA-4,
CD226 competes with TIGIT for ligand (Stengel et al., 2012). The
expression kinetics of the two receptor pairs are also similar in
that expression of both TIGIT and CTLA-4 is induced upon
activation, whereas CD226 and CD28 are expressed by both
naive and effector T cells. CD226 has been shown to support
antiviral and antitumor immune responses (Cella et al., 2010;
Welch et al., 2012; Ramsbottom et al., 2014). The molecular
and functional relationships between TIGIT and CD226 are
poorly characterized, and TIGIT’s role in CD8+ T cell responses
and their exhaustion has been unknown. Here we show that
TIGIT is a critical regulator of antitumor and antiviral CD8+
T cell responses.924 Cancer Cell 26, 923–937, December 8, 2014 ª2014 Elsevier Inc.RESULTS
TIGIT Is Highly Expressed in Human Tumors and
Correlated with CD8+ T Cell Infiltration
To identify genes associated with tumor-infiltrating T cells, we
used a gene signature-based approach to interrogate gene
expression data from the Cancer Genome Atlas lung squamous
cell carcinoma (LUSC) collection (Network, 2012b). Using im-
mune cell-specific gene sets defined by the Immune Response
In Silico (IRIS) project (Abbas et al., 2005), we identified a highly
specific 15-gene signature for tumor-associated T cells (see
Experimental Procedures and Figure S1 available online). Within
this T cell signature, we identified several coinhibitory receptors
associated with T cell dysfunction in tumors, particularly PD-1
(Figure S1).We also identified TIGIT, a T cell coinhibitory receptor
not previously associated with antitumor responses (Figure S1
and Table S1). TIGIT expression was also highly correlated with
CD3ε expression (Spearman’s rank correlation coefficient (r) of
0.82; Figure 1A). Similarly, in colon adenocarcinoma (COAD),
uterine corpus endometroid carcinoma (UCEC), breast carci-
noma (BRCA), and kidney renal clear cell carcinoma (KIRC)
(Network, 2012a, 2012c, 2013; Kandoth et al., 2013), TIGIT and
CD3ε were highly correlated (r = 0.83–0.94; Figures 1B–1E).
Furthermore, the TIGIT:CD3ε expression ratio was increased
significantly in LUSC, COAC, UCEC, and BRCA tumor samples
compared with matched normal tissue (116%–419% increase;
Figures 1A–1D). The TIGIT:CD3ε expression ratio in KIRC sam-
ples was unchanged, although expression of both TIGIT and
CD3ε was much higher in tumor samples than in normal tissue
samples (Figure 1E). Thesedata indicated that TIGITwasupregu-
lated by T cells in a broad range of solid tumors.
TIGIT has been described previously as an inhibitor of CD4+
T cell priming with no known function in CD8+ T cells. TIGIT
expression in LUSC samples was highly correlated with CD8A
and to a lesser extent with CD4 (r = 0.77 and 0.48 respectively;
Figure 1F). Expression of TIGIT was also correlated with expres-
sion of its complementary costimulatory receptor, CD226, as
well as with expression of PD-1, a key mediator and marker of
T cell dysfunction in tumors and during other chronic immune
responses (r = 0.64 and 0.82 respectively; Figures 1G–1H).
These data suggested that tumor-infiltrating lymphocyte (TIL)
T cells, particularly exhausted CD8+ T cells, may express high
levels of TIGIT.
TIGIT and PD-1 Are Coordinately Expressed by Human
and Murine Tumor-Infiltrating Lymphocytes
To confirm protein expression of TIGIT by tumor-infiltrating
T cells, we assessed surface TIGIT expression in human non-
small-cell lung carcinomas (NSCLC) by fluorescence-activated
cell sorting (FACS). TIGIT was expressed by a large percentage
of NSCLC-infiltrating CD8+ T cells (58% TIGIT+; Figure 2A).
Consistent with the correlation between TIGIT and PD-1 RNA
expression found in Figure 1, nearly all CD8+ T cells expressing
TIGIT also expressed high levels of PD-1 (Figure 2B; Figure S2).
A smaller subset of NSCLC-infiltrating CD4+ T cells similarly
coexpressed TIGIT and PD-1 (28%TIGIT+; Figure 2C; Figure S2).
Interestingly, peripheral CD8+ and CD4+ T cells from NSCLC
tumor donors also expressed higher levels of TIGIT than cells






Figure 1. TIGIT Expression Is Elevated in Human Cancer and Strongly Correlated with CD8 and PD-1
Gene expression analyses of human cancers were performed as described (see Experimental Procedures). Scatter plots show per-gene count data normalized
by library size. Box and whisker plots show the variance-stabilized expression ratio of TIGIT and CD3ε.
(A) Correlation of TIGIT and CD3ε RNA expression in LUSC (red) and normal lung (black). r = 0.86. Quantification of TIGIT/CD3ε expression ratios is also shown.
LUSC ratio increase = 372%. ***p = 1.46 3 1046.
(B) Correlation of TIGIT and CD3εRNA expression in COAD (red) and normal colon (black). r = 0.83. Quantification of TIGIT/CD3ε expression ratios is also shown.
COAD ratio increase = 116%. ***p = 3.66 3 106.
(C) Correlation of TIGIT andCD3εRNA expression in UCEC (red) and normal uterine endometrium (black). r = 0.87. Quantification of TIGIT/CD3ε expression ratios
is also shown. UCEC ratio increase = 419%. ***p = 7.41 3 105.
(D) Correlation of TIGIT andCD3εRNA expression in BRCA (red) and normal breast (black). r = 0.82. Quantification of TIGIT/CD3ε expression ratios is also shown.
BRCA ratio increase = 313%. ***p = 4.6 3 1044.
(E) Correlation of TIGIT and CD3ε RNA expression in kidney renal clear cell carcinoma (red) and normal kidney (black). r = 0.94. Quantification of TIGIT/CD3ε
expression ratios is also shown.
(F) Correlation of TIGIT and CD8A (left) or TIGIT and CD4 (right) RNA expression in lung squamous cell carcinoma (red) and normal lung (black). r = 0.77 and 0.48,
respectively.
(G) Correlation of TIGIT and PD-1 (PDCD1) RNA expression in lung squamous cell carcinoma (red) and normal lung (black). r = 0.82.
(H) Correlation of TIGIT and CD226 RNA expression in lung squamous cell carcinoma (red) and normal lung (black). r = 0.64.
See also Figure S1 and Table S1.
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Figure 2. TIGIT and PD-1 Are Coordinately Expressed by Human and Murine Tumor-Infiltrating Lymphocytes
(A–D) Analysis of lymphocytes from resected human NSCLC tumors, tumor-matched peripheral blood, and normal donor peripheral blood. Data are pooled from
three independently acquired sets of samples.
(A) Representative FACS plots of TIGIT expression by peripheral and tumor-infiltrating CD8+ T cells. Shown is the quantitation of TIGIT+ cells as a percentage of all
CD8+ T cells. *p < 0.05.
(B) Flow cytometry histogram representative of TIGIT expression by PD-1high (red) and PD-1low (blue) tumor-infiltrating CD8+ T cells.
(C) Representative FACS plots of TIGIT expression by peripheral and tumor-infiltrating CD4+ T cells. Shown is the quantitation of TIGIT+ cells as a percentage of all
CD4+ T cells.
(D) Flow cytometry histogram representative of TIGIT expression by PD-1high (red) and PD-1low (blue) tumor-infiltrating CD4+ T cells.
(E and F) BALB/c mice were inoculated with syngeneic CT26 colorectal carcinoma cells. Splenocytes and TILs were analyzed 14 days after inoculation when
tumors had reached approximately 200 mm3 in size. Data are representative of more than three independent experiments (n = 5-6). Shown is a representative
FACS plot of TIGIT expression by tumor-infiltrating (E) CD8+ T cells and (F) CD4+ T cells, with TIGIT+ cells boxed. Also shown is the quantitation of the frequency of
TIGIT+ T cells as a percentage of all T cells. *p = 0.0134, ***p < 0.0001.
(G) Flow cytometry histogram representative of TIGIT expression by PD-1high and PD-1low tumor-infiltrating CD8+ T cells and by splenic CD8+ T cells. Quantitation
of TIGIT MFI is also shown. **p = 0.0023.
(H) Flow cytometry histogram representative of TIGIT expression by PD-1high and PD-1low tumor-infiltrating CD4+ T cells and by splenic CD4+ T cells. Quantitation
of TIGIT MFI is also shown. ***p = 0.0002.
Error bars depict SEM. See also Figure S2.
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Figure 3. TIGIT andPD-L1BlockadesSyner-
gistically Elicit Tumor Rejection
(A–C) BALB/c mice were inoculated subcutane-
ously with CT26 colorectal carcinoma cells in their
right thoracic flanks. When tumors reached
approximately 200 mm3 in size, mice were treated
with isotype control (black), anti-PD-L1 + control
(red), anti-TIGIT + control (blue), or anti-PD-L1 +
anti-TIGIT (purple) antibodies for 3 weeks. Data are
representative of more than three independent
experiments (A and B) or two independent exper-
iments (C) [n = 10 (A and B) or 7–10 (C)].
(A) Median (left) and individual (right) CT26 tumor
volumes over time. On day 12, ***p < 0.001 be-
tween mice treated with anti-PD-L1 + anti-TIGIT
and all other groups.
(B) Mouse survival over time.
(C) Approximately 60 days after initial inoculation,
mice that received anti-TIGIT + anti-PD-L1 and
reached CR, as well as naive control mice, were
(re)inoculated with CT26 cells in their left thoracic
flanks and inoculated with EMT6 breast carcinoma
cells in their mammary fat pads. Median (left) and
individual (right) tumor volumes for CT26 (squares)
and EMT6 (triangles) in CRmice (purple and green)
and naive mice (black and orange) are shown.
See also Figure S3.
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TIGIT Limits Antitumor CD8+ T Cell Responsesobtained in a set of matched colorectal carcinoma (CRC) and pe-
ripheral blood mononuclear cell (PBMC) samples (Figure S2).
TIGIT was not expressed by myeloid cells, tumor cells, or other
nonhematopoietic cells (Figure S2).
We then characterized TIGIT expression in the murine synge-
neic CT26 and EMT6 tumor models. Twoweeks postinoculation,
when CT26 and EMT6 tumors had grown to 150–200mm3 in size
and were robustly infiltrated by T cells, TIGIT was expressed by
approximately 50% of CD8+ TILs and 25%of CD4+ TILs at levels
similar to those of primary CD8+ T cells stimulated in vitro (Fig-
ures 2D and 2E; Figure S2). In both CD8+ and CD4+ murine
TILs, CD226 was constitutively expressed, and TIGIT and PD-1
expression remained highly correlated (Figures 2F and 2G; Fig-
ure S2). TIGIT was not expressed by tumor cells or other nonhe-
matopoietic cells (Figure S2).
These results confirmed that TIGIT was highly expressed by
TILs and that expression of TIGIT occurred in parallel with
expression of other coinhibitory receptors, most notably PD-1.
Given the central role of PD-1 in mediating T cell exhaustion,
we hypothesized that TIGIT could similarly act as a checkpoint
inhibitor of chronically stimulated or exhausted tumor-infiltrating
T cells.
TIGIT and PD-1 Blockades Synergistically Elicit CD8+
T Cell-Mediated Tumor Rejection
To test the hypothesis that TIGIT regulates antitumor responses,
mice were inoculated with CT26 tumor cells and, when tumorsCancer Cell 26, 923–937,were 150–200 mm3 in volume, treated
with blocking antibodies against TIGIT
(Yu et al., 2009), PD-L1, or a combination
of both for 3 weeks. Tumor growth was
assessed during and after treatment. Inthis model, single-agent treatment with anti-TIGIT or anti-PD-
L1 was insufficient to decrease the tumor burden and increased
median survival only by approximately 3 days (Figures 3A and
3B). However, coblockade of TIGIT and PD-L1 led to a striking
reversal of tumor growth (75% decrease in mean tumor volume
after 16 days of treatment, p < 0.0001; Figure 3A). Themajority of
mice receiving the combination treatment achieved a complete
response (CR) for the duration of the study, even in the absence
of further treatment (Figures 3A and 3B). These effects were also
observed in CT26 tumor-bearing mice treated with a combina-
tion of blocking antibodies against TIGIT and PD-1 (data not
shown) and in mice inoculated with syngeneic EMT6 breast car-
cinoma cells (Figure S3). Furthermore, mice that previously
cleared CT26 tumors mounted a protective antitumor response
to reinoculated CT26 tumors but not to novel EMT6 tumors (Fig-
ure 3C). These data indicated the induction of tumor antigen-
specific immunity in treated mice.
Next, CT26-tumor bearing mice were subjected to temporary
CD8+ T cell ablation using depleting antibodies prior to treatment
with anti-TIGIT and anti-PD-L1. Peripheral CD8+ T cell depletion
was confirmed 5 days after treatment by FACS (data not shown).
Mice treated with anti-TIGIT and anti-PD-L1 were unable to
reject CT26 tumors when depleted of CD8+ T cells at the start
of treatment (1,532% increase in mean tumor volume after
17 days of treatment, p = 0.0004; Figures 4A and 4B). Addition-
ally, CD8+ T cell depletion impaired the ability of CR mice to
control reinoculated CT26 tumors (Figure 4C). These dataDecember 8, 2014 ª2014 Elsevier Inc. 927
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Figure 4. TIGIT/PD-L1 Coblockade Efficacy
Is Dependent on CD8+ T Cells
(A and B) Wild-type BALB/c mice were inoculated
with CT26 tumors. When tumors reached 100–
150mm3 in size,micewere temporarily depleted of
CD8+ T cells and treated with anti-TIGIT + anti-PD-
L1 or control antibodies as described in Figure 3.
Data are representative of two independent ex-
periments (n = 10).
(A) Median (left) and individual (right) CT26 tumor
volumes over time.
(B) Quantitation of CT26 tumor volumes 17 days
after the start of treatment. ***p = 0.0004.
(C) Wild-type BALB/c mice were inoculated with
CT26 tumors and treated with anti-TIGIT + anti-
PD-L1 and subsequently rechallenged with CT26
tumors (as described in Figure 3) with temporary
depletion of CD8+ T cells at the time of rechallenge.
Data are representative of two independent ex-
periments (n = 5). Median (left) and individual (right)
CT26 tumor volumes over time are shown.
Error bars depict SEM.
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TIGIT Limits Antitumor CD8+ T Cell Responsesdemonstrated that anti-TIGIT and anti-PD-L1 acted through
CD8+ T cells to elicit effective primary and secondary antitumor
immune responses.
TIGIT Regulates Tumor-Infiltrating CD8+ T Cell Effector
Function
Consequently, we assessed the functional consequences of
TIGIT and PD-L1 inhibition on TILs and tumor-draining lymph
node-resident T cells. CT26 tumor-bearing mice were treated
with anti-TIGIT and/or anti-PD-L1 antibodies as described
above. After 7 days of treatment, when tumors had grown to
approximately 500 mm3 in size, tumors and tumor-draining
lymph nodes were analyzed by FACS. Tumor-draining lymph
node-resident CD8+ T cells from mice treated with anti-TIGIT
alone, anti-PD-L1 alone, or anti-TIGIT plus anti-PD-L1 all ex-
hibited enhanced interferon g (IFNg) production relative to con-
trol mice (75%–113% increase, p < 0.001; Figures 5A and 5B).
However, only tumor-infiltrating CD8+ T cells from mice treated
with both anti-TIGIT and anti-PD-L1 showed a significant in-
crease in IFNg production (274% relative to isotype-treated co-
horts, p = 0.0001; Figures 5A and 5C), consistent with the current
understanding that tumor microenvironments are highly immu-
nosuppressive and can induce more profound levels of T cell
dysfunction. The frequencies of IFNg/tumor necrosis factor a928 Cancer Cell 26, 923–937, December 8, 2014 ª2014 Elsevier Inc.(TNF-a) dual-producing CD8+ T cells in
tumors and tumor-draining lymph nodes
followed similar patterns (Figures 5D
and 5E). TIGIT/PD-L1 coblockade also
induced slightly higher frequencies of
CD8+ TILs but not tumor-draining lymph
node-resident CD8+ T cells (Figure S4).
Unlike CD8+ T cells, effector CD4+ T cell
activation and cytokine production were
unaffected by treatment (Figures 5B–5E;
Figure S4). Some immunoreceptor-tar-
geting antibodies, such as anti-CTLA-4and anti-GITR, have been shown to elicit tumor rejection primar-
ily by mediating regulatory T cell (Treg) cell depletion (Bulliard
et al., 2013; Simpson et al., 2013). In contrast, treatment with
anti-TIGIT and anti-PD-L1 did not reduce tumor-infiltrating Treg
frequencies (Figure S4).
These data suggested that inhibition of TIGIT and PD-L1
selectively and synergistically enhanced CD8+ T cell effector
function, in agreement with the requirement for CD8+ T cells in
anti-TIGIT/PD-L1 treatment efficacy (Figure 4).
TIGIT Enforces CD8+ T Cell Exhaustion during Chronic
Viral Infection
To determine whether TIGIT had a broader role in other sup-
pressed T cell responses, we used models of viral infection
(Barber et al., 2006; Blackburn et al., 2009; Wherry et al.,
2007). Mice acutely infected with the Armstrong strain of
LCMV mount a robust immune response and rapidly clear the
virus. In this model, TIGIT was highly expressed by approxi-
mately 80% of effector (Teff) CD8
+ T cells and 40% of CD4+ Teff
cells (Figure 6A). Interestingly, TIGIT expression was highest on
CD8+ Teff cells that also expressed high levels of PD-1, consis-
tent with TIGIT/PD-1 coexpression in tumors (Figure 6B).
Furthermore, in mice chronically infectedwith the Clone 13 strain




Figure 5. TIGIT Regulates Tumor-Infiltrating
CD8+ T Cell Effector Function
BALB/C mice were inoculated subcutaneously
with CT26 colorectal carcinoma cells in their right
thoracic flanks and treated with control, anti-PD-
L1 + control, anti-TIGIT + control, or anti-PD-L1 +
anti-TIGIT, as described in Figure 3. Tumor-drain-
ing lymph node (dLN)-resident and tumor-infil-
trating T cells were analyzed by flow cytometry
7 days after the start of treatment. Data are
representative of more than three independent
experiments (n = 5).
(A) Representative FACS plots of dLN-resident and
tumor-infiltrating CD8+ T cells after stimulation
ex vivo, with IFNg+ cells boxed.
(B) Quantitation of IFNg-producing dLN-resident
CD8+ and CD4+ T cells as percentages of total
dLN-resident CD8+ and CD4+ T cells, respectively.
IFNg production by unstimulated (no stim.) T cells
is also shown. ***p < 0.001.
(C) Quantitation of IFNg-producing tumor-infil-
trating CD8+ and CD4+ T cells as percentages of
total tumor-infiltrating CD8+ and CD4+ T cells,
respectively. IFNg production by unstimulated
T cells is also shown. ***p = 0.0003.
(D) Quantitation of IFNg/TNFa dual-producing
dLN-resident CD8+ and CD4+ T cells as percent-
ages of total dLN resident CD8+ and CD4+ T cells,
respectively. Dual cytokine production by un-
stimulated T cells is also shown. **p = 0.002, 0.003,
and 0.001, respectively.
(E) Quantitation of IFNg/TNFa dual-producing
tumor-infiltrating CD8+ and CD4+ T cells as per-
centages of total tumor-infiltrating CD8+ and CD4+
T cells, respectively. Dual cytokine production by
unstimulated T cells is also shown. ***p < 0.0001.
Error bars depict SEM. See also Figure S4.
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central memory T cells, or naive T cells, consistent with a recent
report (Figure 6C; Doering et al., 2012).
We then tested mice in which TIGIT expression was selec-
tively ablated in T cells (TIGITfl/fl;CD4cre; Figure S5). The
absence of TIGIT had no appreciable effects on T cell develop-
ment or the overall response to acute viral infection with the
Armstrong strain of LCMV (Figure S5). However, upon chronic
infection with the Clone 13 strain of LCMV, viral loads were
reduced significantly, and CD8+ and CD4+ T cell cytokine pro-
duction was increased significantly in TIGITfl/fl CD4-cre+ mice
relative to wild-type littermates (Figure S5). These data sug-
gested that TIGIT deficiency could enhance T cell responses
to chronic viral infection, although were unable to distinguish
between potential roles for TIGIT during the early stages of
T cell priming and/or the later stages of chronic T cell stimula-
tion and dysfunction.
To distinguish these two possibilities, we treatedmice with es-
tablished chronic LCMV infection with anti-TIGIT and/or anti-PD-
L1. Blockade of the PD-1/PD-L1 pathway alone significantly
reduced viral titers in mice compared with mice treated with iso-
type-matched control antibodies (68% decrease, p = 0.0004;CaFigure 6D), consistent with previous reports (Barber et al.,
2006). Treatment with anti-TIGIT alone did not significantly affect
viral titers, but anti-TIGIT did act synergistically with anti-PD-L1
to enhance viral clearance (74% decrease in viral titers over
treatment with anti-PD-L1 treatment alone, p = 0.0045; Fig-
ure 6D). Functional characterization of T cell effector function
in chronically infected mice confirmed that PD-L1 blockade
alone robustly enhanced CD8+ T cell activation and moderately
increased IFNg production relative to treatment with matched
isotype control antibodies (88% increase and 37% increase,
respectively, p < 0.05; Figure 6E). Mice treated with anti-TIGIT
alone did not have enhanced CD8+ or CD4+ T cell activation or
cytokine competency, suggesting that TIGIT blockade alone
was insufficient to restore effector function in T cells that were
already exhausted (Figure 6E). However, as in tumor models,
TIGIT/PD-L1 coblockade significantly enhanced CD8+ T cell
effector function, but not CD4+ T cell effector function, in mice
compared with mice treated with anti-PD-L1 alone (93% in-
crease, p = 0.0050; Figure 6F; Figure S5). Similar effects on
T cell expansion and effector function were observed in LCMV
gp33 antigen-specific T cells (Figure S5). Taken together with






Figure 6. TIGIT Enforces CD8+ T Cell Exhaustion during Chronic Viral Infection
(A and B) C57BL6/J mice were infected with the Armstrong strain of LCMV, and splenocytes were analyzed 7 days after infection. Data are representative of two
independent experiments (n = 5).
(A) Flow cytometry histogram representative of TIGIT expression by naive (CD44lowCD62Lhigh) and effector (CD44highCD62Llow) CD4+ and CD8+ T cells.
Quantitation of TIGIT+ cells as a percentage of naive and effector memory (Teff) CD4+ and CD8+ T cells is also shown. ***p < 0.001.
(B) Flow cytometry histogram representative of TIGIT expression by PD-1high and PD-1low effector CD8+ T cells. Quantitation of TIGIT MFI is also shown.
***p < 0.001.
(C) C57BL6/J mice were briefly depleted of CD4+ T cells and infected with the Clone 13 strain of LCMV. Splenocytes were analyzed 42 days after infection.
Shown is a flow cytometry histogram representative of TIGIT expression by naive (CD44lowCD62Lhigh), central memory (CD44highCD62Lhigh), and effector
memory (CD44highCD62Llow) CD8+ T cells. Quantitation of TIGIT MFI is also shown. ***p < 0.001. Data are representative of two independent experiments
(n = 5).
(D–F) C57BL6/J mice were briefly depleted of CD4+ T cells and infected with the Clone 13 strain of LCMV. Mice were treated with isotype-matched control, anti-
PD-L1 + control, anti-TIGIT + control, or anti-PD-L1 + anti-TIGIT antibodies starting 28 days after infection. Splenocytes and liver viral titers were analyzed 42 days
after infection. Data are representative of two independent experiments (n = 10).
(D) Quantitation of liver LCMV titers. *p = 0.0106, **p = 0.0047.
(legend continued on next page)
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TIGIT Limits Antitumor CD8+ T Cell Responsesstrong synergy between PD-1 and TIGIT on exhausted CD8+
T cells and indicate that TIGIT specifically regulates CD8+
T cell cytokine competency and effector function.
TIGIT Impairs CD226 Function by Directly Disrupting
CD226 Homodimerization
TIGIT contains an ITIM-like motif. However, unlike PD-1 or
CTLA-4, there is no direct biochemical evidence of a T cell inhib-
itory signaling cascade initiated by endogenous TIGIT (Joller
et al., 2011; Lozano et al., 2012; Yu et al., 2009). Some inhibitory
receptors also function to suppress T cell responses by limiting
complementary costimulatory receptor activation, as is the
case with CTLA-4-mediated suppression of CD28 signaling
(Pentcheva-Hoang et al., 2004). Consequently, we asked
whether TIGIT induced T cell exhaustion indirectly via suppres-
sion of its complementary costimulatory receptor, CD226, which
is highly expressed by peripheral and tumor-infiltrating CD8+
T cells (Figure S6). TIGIT-deficient murine CD8+ T cells were
stimulated with suboptimal levels of anti-CD3 with or without re-
combinant murine PVR-Fc fusion protein. In the absence of
TIGIT, T cells responded more robustly to PVR costimulation
than T cells from wild-type littermates, and this enhanced
response was dependent on CD226 (46% increase in prolifera-
tion, p = 0.0061; Figure 7A). Consistent with these data, the
proliferation of wild-type murine CD8+ T cells stimulated with
anti-CD3 and PVR was enhanced significantly by addition of
anti-TIGIT blocking antibodies relative to isotype-matched con-
trol antibodies (p = 0.0010; Figure 7B). This effect was again
dependent on CD226 (Figure 7B). To test the relevance of TIGIT
to primary human CD8+ T cells, we purified CD8+ T cells from
healthy donor blood and stimulated them with suboptimal levels
of anti-CD3 and recombinant human PVR-Fc fusion proteins. In
the presence of isotype-matched control antibodies, PVR costi-
mulation moderately enhanced T cell stimulation and prolifera-
tion. Again, addition of anti-TIGIT blocking antibodies signifi-
cantly enhanced the effects of PVR costimulation (69%
increase in proliferation, p = 0.0071; Figure 7C). These data
demonstrated a cell-intrinsic role for TIGIT inhibition of CD226
function on primary murine and human CD8+ T cells.
To determine the molecular mechanism by which TIGIT
impaired CD226 activity, we utilized time-resolved fluorescence
resonance energy transfer (TR-FRET) (Bazin et al., 2002; Keppler
et al., 2004; Maurel et al., 2008). First, we expressed and labeled
human ST-CD226 with nonpermeant donor and acceptor fluoro-
phores. These cells yielded a strong FRET signal, confirming the
ability of CD226 to homodimerize (Figure 7D). To monitor CD226
and TIGIT interactions on the cell surface, we expressed ST-
CD226 in the absence or presence of human hemagglutinin
(HA)-TIGIT and labeled the two molecules with the SNAP tag
substrate and anti-HA antibodies, respectively. Strikingly,
expression of TIGIT (monitored by ELISA; Figure S6) attenuated
the CD226/CD226 FRET signal in a dose-dependent manner,
indicating that TIGIT could disrupt CD226 homodimerization(E) Representative FACS plots gated on CD8+ T cells, with activated cells (CD44hig
of total CD8+ T cells. ***p < 0.0001.
(F) Representative FACS plots gated on activated CD8+ T cells after stimulatio
percentage of activated CD8+ T cells.*p = 0.0352, **p = 0.0047.
Error bars depict SEM. See also Figure S5.
Ca(Figure 7E). Indeed, the use of acceptor CD226 and donor TIGIT
also resulted in a significant FRET signal, revealing a direct inter-
action between the two proteins (Figure 7F). This interaction was
further confirmed by coimmunoprecipitation (Figure 7G). To test
the effects of TIGIT antibody blockade on TIGIT-CD226 interac-
tion, we coexpressed human ST-CD226 and HA-TIGIT in the
presence or absence of blocking antibodies against human
TIGIT. The addition of anti-TIGIT to the cell cultures significantly
reduced the ability of TIGIT and CD226 to associate (Figure 7H),
consistent with ability of anti-TIGIT to enhance CD226 costimu-
lation (Figure 6). Next we confirmed the capacity of endogenous
TIGIT and CD226 to interact. Primary human T cells were stimu-
lated in vitro with anti-CD3 and anti-CD28, sorted on the basis of
TIGIT expression, rested, restimulated, and labeled with
antibodies against endogenous TIGIT and CD226 that were con-
jugated to fluorophores compatible with TR-FRET. TIGIT-ex-
pressing T cells labeled with donor-conjugated anti-TIGIT and
acceptor-conjugated anti-CD226 antibodies yielded a strong
FRET signal. In contrast, only a negligible FRET signal was de-
tected on T cells that did not express TIGIT or that were labeled
with donor-conjugated anti-TIGIT and acceptor-conjugated
anti-herpes virus entry mediator (HVEM) antibodies, confirming
the specificity of the detected interaction between endogenous
TIGIT and CD226.
These data demonstrated that TIGIT and CD226 could directly
interact at the cell surface and that this interaction impaired
CD226 homodimerization. Given the role of CD226 as a costimu-
lator of T cell responses in vivo, we hypothesized that suppres-
sion of CD226may be a keymechanism of action by which TIGIT
enforces CD8+ T cell exhaustion during chronic viral infection
and cancer.
TIGIT Suppression of CD8+ T Cell Responses
Is Dependent on CD226
To assess the requirement of CD226 for the anti-TIGIT mediated
rescue of effector T cell responses, we treated CT26 tumor-
bearing mice as before with the addition of either blocking
anti-CD226 antibodies or control antibodies. Treatment with
anti-CD226 alone slightly accelerated tumor growth relative to
control mice, resulting in a decreased median survival of
2 days (anti-CD226 alone versus control, p = 0.0118; Figures
8A and 8B). Strikingly, the addition of anti-CD226 blocking anti-
bodies to mice treated with anti-TIGIT and anti-PD-L1 coblock-
ade reversed the effects of TIGIT/PD-L1 coblockade on tumor
regression and survival (Figures 8A and 8B). A similar effect
was observed on LCMV titers in chronically infectedmice treated
with anti-TIGIT, anti-PD-L1, and/or anti-CD226 (Figure S7),
suggesting that TIGIT limits CD226 activity during both antitumor
and antiviral T cell responses.
Next we assessed T cells from CT26 tumors and tumor-drain-
ing lymph nodes inmice treated as above for 7 days. Blockade of
CD226 alone had no effect on IFNg production by tumor-infil-
trating and tumor-draining lymph node-resident CD8+ T cells,hCD62Llow) boxed. Shown is the quantitation of activated cells as a percentage
n in vitro, with IFNg+ cells boxed. Quantitation of IFNg-producing cells as a





Figure 7. TIGIT Impairs CD226 Function by Directly Disrupting CD226 Homodimerization
(A) CD8+ T cells were MACS-enriched from TIGITfl/fl CD4cre (CKO) and TIGITfl/fl CD4wt (WT) littermates and stimulated in the presence of anti-CD226 or isotype-
matched control antibodies as indicated. H3-thymidine uptake is shown as a ratio relative towild-type cells culturedwithout stimulation or treatment. **p = 0.0061,
***p < 0.0001. Data are representative of two independent experiments (n = 5).
(B) Wild-type C57BL6/J CD8+ T cells were MACS-enriched and stimulated in the presence of anti-TIGIT, anti-CD226, and/or isotype-matched control antibodies
as indicated. H3-thymidine uptake is shown as a ratio relative to cells cultured without stimulation or treatment. ***p < 0.001 in paired t tests.
(C) Primary human CD8+ T cells were MACS-enriched from blood and stimulated with suboptimal levels of plate-bound anti-CD3 in the presence or absence of
human recombinant PVR-Fc. Anti-TIGIT antibodies or isotype-matched control antibodies were added as indicated. Shown is the quantitation of 3H-thymidine
uptake. **p = 0.0071 and 0.0014, respectively.
(D) CHO cells were transiently transfected with increasing concentrations of acceptor (green ‘‘A’’) and donor (gray ‘‘D’’) FLAG-ST-CD226 as indicated. Shown is
the quantification of FRET intensity relative to donor emission. Data are representative of three independent experiments (n = 3).
(E and F) CHO cells were transiently transfected with human FLAG-ST-CD226 and with increasing concentrations of human HA-TIGIT as indicated. Data are
representative of two or more independent experiments (n = 4). Data are normalized to the maximal signal.
(E) Quantification of the CD226:CD226 FRET ratio.
(F) Quantification of the TIGIT:CD226 FRET ratio.
(legend continued on next page)
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exhausted T cells is limited (Figures 8C-8F). As before, coblock-
ade of PD-L1 and TIGIT enhanced IFNg production by both tu-
mor-infiltrating and tumor-draining lymph node-resident CD8+
T cells (130% and 99% increase, respectively, p < 0.001; Figures
8C and 8D). CD226 blockade impaired the effector function and
frequency of CD8+ TILs in mice treated with anti-TIGIT and anti-
PD-L1 (57% decrease, p = 0.0015; Figure 8C) but had no effect
on tumor-draining lymph node-resident CD8+ T cells in these
mice (Figures 8D and 8F). Because anti-PD-L1 alone was suffi-
cient to enhance CD8+ T cell effector function in tumor-draining
lymph nodes but both anti-TIGIT and anti-PD-L1 were needed to
restore CD8+ T cell effector function in tumors, these data sug-
gested that anti-CD226 selectively abrogated the effects of
anti-TIGIT and not those of anti-PD-L1.
Taken together, these results reveal critical and antagonistic
roles for TIGIT and CD226 in regulating the effector function of
chronically stimulated CD8+ T cells in vivo.
DISCUSSION
The induction of an effective anti-tumor T cell response requires
passage through several checkpoints: antigen-specific priming,
effector cell differentiation, trafficking to the tumor bed, and,
finally, killing of the tumor cells by cytotoxic CD8+ T cells (Chen
and Mellman, 2013). However, the immunosuppressive nature
of tumor microenvironments often preempts this last step by
rendering the infiltrating T cells dysfunctional and unable to elab-
orate their full effector functions. Remarkably, this so-called
exhaustion can be rapidly reversed in at least some T cells
upon antagonism of key coinhibitory receptors. These receptors
are expressed by CD8+ and CD4+ T cells and by innate immune
cells, and their effects on each lineage can potently and coordi-
nately suppress immune responses. TIGIT has been described
as a modest inhibitor of CD4+ T cell priming and NK cell killing.
However, its importance to CD8+ T cells and to antitumor and
other chronic immune responses has been untested. Here we
show that TIGIT is highly expressed by both human and murine
tumor-infiltrating CD8+ T cells. TIGIT was expressed in parallel
with PD-1, a key T cell checkpoint inhibitor during chronic
immune responses. In CT26 tumor-bearing mice, antibody
blockade of both TIGIT and PD-L1 was required to elicit tumor
rejection and antigen-specific protection against tumor rechal-
lenge. Indeed, although blockade of either TIGIT or PD-L1 alone
was sufficient to enhance CD8+ T cell effector function within
tumor-draining lymph nodes, blockade of both receptors was
necessary to restore the potency of CD8+ T cells within highly
suppressive tumor microenvironments. Taken together, these
results identify TIGIT as a critical and specific regulator of the
effector function of chronically stimulated CD8+ T cells in addi-
tion to its roles in other immune cell lineages.(G) Anti-FLAG (left) and anti-HA (right) immunoblots (IB) performed on either anti-F
with either an empty pRK vector or a combination of FLAG-CD226 and HA-TIGIT
(H) CHO cells were transfected as in (F), and the TIGIT:CD226 FRET ratio was qua
representative of four independent experiments (n = 3).
(I) Primary human T cells were MACS-enriched from blood and stimulated w
restimulated, and labeled for FRET with the indicated antibodies. Data are repres
ratios. ***p < 0.001.
Error bars depict SEM. See also Figure S6.
CaSimilarly, T cells in the canonical LCMV model of chronic viral
infection and T cell exhaustion coordinately expressed TIGIT and
PD-1. Blockade of both receptors synergistically hastened viral
clearance and greatly enhanced CD8+ T cell effector function.
Genetic deletion of TIGIT was sufficient to enhance both CD8+
and CD4+ T cell effector function and to improve viral clearance.
However, mice with established chronic infections required
treatment with both anti-TIGIT and anti-PD-L1 to reveal a
specialized role for TIGIT in limiting the effector function of
chronically stimulated CD8+ T cells. These results distinguish
two functions for TIGIT: one to limit T cell priming, which impacts
both CD4+ and CD8+ T cell responses, and a second, more
potent and specialized role in the suppression of effector func-
tion in chronically stimulated CD8+ T cells. This second role
may be subordinate to PD-1, consistent with PD-1’s status as
a key limiter of acute and chronic T cell responses. Indeed, the
absence of TIGIT in and of itself was not sufficient to perturb
the T cell response to acute viral infection, in marked contrast
to the lethal consequences of PD-L1 ablation in similar settings
(Barber et al., 2006; Mueller et al., 2010).
Coinhibitory receptors can suppress immune responses by
direct signaling in cis, by inducing ligand signaling in trans, and
by competitionwith costimulatory receptors. The firstmechanism
bywhich TIGITwas found to inhibit T cell responseswas signaling
through ligation of its ligand PVRon dendritic cells, resulting in the
conversion of those dendritic cells to a tolerogenic phenotype
characterized by increased IL-10 anddecreased IL-12production
(Yuetal., 2009).Theabsenceof IL-10wassufficient to fully reverse
the effects of TIGIT signaling in a model of T cell hypersensitivity,
suggesting that thiswas the predominantmechanismof action by
which TIGIT suppressed acute CD4+ T cell responses (Yu et al.,
2009). AlthoughTIGIT signaling in cis has been described in trans-
fectedNKcell lines (Liu et al., 2013), only indirect evidenceofTIGIT
signaling in T cells has been reported (Joller et al., 2011; Lozano
et al., 2012; Yu et al., 2009). Further studies are needed to clarify
the capacity of TIGIT to signal in T cells and the effects of this
signaling on CD4+ and CD8+ T cell responses. TIGIT may also
act to directly compete with costimulatory receptors, particularly
CD226, for ligand binding (Lozano et al., 2012; Stengel et al.,
2012; Yuet al., 2009). CD226deficiency hasbeen shown to impair
antiviral and antitumor T cell effector function (Cella et al., 2010;
Ramsbottomet al., 2014;Welch et al., 2012); however, themolec-
ular relationship between TIGIT and CD226 has not been fully
elucidated. Here we showed that TIGIT directly interacts with
CD226 and that this interaction impaired CD226 homodimeriza-
tion and function. CD226 costimulation was enhanced in primary
human andmurine CD8+ T cells treated with an antibody that dis-
rupted TIGIT-CD226 interaction in vitro, and treatment of tumor-
bearingmicewith anti-CD226 antibodies was sufficient to abolish
the effects of anti-TIGIT in vivo. These data depict a relationship
between TIGIT and CD226 that echoes that of CTLA-4 andLAG or anti-HA immunoprecipitates (IP) prepared fromCOS-7 cells transfected
. Data are representative of two independent experiments.
ntified after treatment with PBS (white) or anti-TIGIT (red). ***p < 0.001. Data are
ith anti-CD3 and anti-CD28. TIGIT+ and TIGIT cells were sorted, rested,
entative of two independent experiments. Shown is the quantification of FRET




Figure 8. TIGIT Suppression of CD8+ T Cell Responses Is Dependent on CD226
(A–F) BALB/c mice were inoculated subcutaneously with CT26 colorectal carcinoma cells in their right thoracic flanks. When tumors reached approximately
200 mm3 in size, mice were treated with isotype control (black), anti-CD226 + control (orange), anti-PD-L1 + control (red), anti-TIGIT + anti-PD-L1 + control
(purple), or anti-TIGIT + anti-PD-L1 + anti-CD226 (green) antibodies for 3 weeks. Data are representative of two independent experiments (n = 10 [A and B] or
5 [C–F]).
(A) Median (left) and individual (right) CT26 tumor volumes over time.
(B) Mouse survival over time.
(C–F) After 7 days of treatment, tumor-infiltrating lymphocytes and tumor-draining lymph node-resident lymphocytes were assessed by flow cytometry.
(C) Quantitation of IFNg-producing CD8+ TILs as a percentage of total CD8+ TILs after stimulation in vitro. **p < 0.01.
(D) Quantitation of IFNg-producing cells as a percentage of tumor-draining lymph node CD8+ T cells after stimulation in vitro. *p < 0.05.
(E) Quantitation of CD8+ TILs as a percentage of total TILs. **p < 0.01.
(F) Quantitation of CD8+ T cells as a percentage of all tumor-draining lymph node-resident lymphocytes.
Error bars depict SEM. See also Figure S7.
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TIGIT Limits Antitumor CD8+ T Cell ResponsesCD28 in that suppression ofCD226activity is a keymechanismby
which TIGIT inhibits CD8+ T cell responses.
Recently, antibody blockade of individual coinhibitory recep-
tors involved in tumor immunosuppression has proven to be
remarkably effective at reversing T cell exhaustion and eliciting
immune rejection of tumors in the clinic. Moreover, targeting a
combination of receptors holds the potential to be even more
effective (Wolchok et al., 2013), making it essential to fully eluci-
date the individual and synergistic functions of the coinhibitory
receptors that regulate antitumor responses. Our findings here
suggest that TIGIT is key checkpoint inhibitor of chronic antiviral934 Cancer Cell 26, 923–937, December 8, 2014 ª2014 Elsevier Inc.and antitumor responses and, consequently, may represent a
target for future immunotherapies.
EXPERIMENTAL PROCEDURES
Bioinformatics
To derive a T cell-specific gene signature, wemanually curated the T cell genes
identified by the IRIS project, removing genes associated with cell cycle pro-
cesses, genes highly expressed in other tissues, and known coactivating
and coinhibitory receptors. We then ranked the genes by their correlation
with the T cell signature in our linear model, choosing only genes positively
correlated with the T cell signature.
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Matched whole blood and fresh surgically resected tumor tissues were ob-
tained from Conversant Biosciences or Foundation Bio. All specimens were
obtained with written informed consent and collected using a protocol
approved by the Hartford Hospital Institutional Review Board (IRB) (NSCLC
patient 1, depicted in Figure 2) or the Western IRB (NSCLC patient 2 and
CRC patient 1, depicted in Figure S2).
Syngeneic Tumor Studies
BALB/cmicewere inoculatedsubcutaneously in the right thoracicflankwith13
105 syngeneic CT26 colon carcinoma cells in Matrigel (BD Biosciences) or in
the fourth mammary fat pad with 1 3 105 syngeneic EMT6 breast carcinoma
cells in Matrigel. After 2 weeks, mice bearing tumors of 150–200 mm3 were
randomized into treatment groups and treated with anti-PD-L1 (10 mg/kg),
anti-TIGIT (25 mg/kg), or isotype control antibodies (to total 35 mg/kg overall
antibody dosing) by intraperitoneal injection three times per week for 3 weeks.
Where indicated, mice received an additional 10 mg/kg of anti-CD226 anti-
bodies or an equivalent amount of control antibodies. For depletion of CD8+
T cells, mice were injected with 250 mg of CD8-depleting antibodies (clone
53.6.7) 1 day before and 3days after tumor inoculation. Tumorsweremeasured
two times per week by caliper, and tumor volumes were calculated using the
modified ellipsoid formula 1/2 3 (length 3 width2). Animals whose tumors
shrank to 32 mm3 or smaller were considered to be in CR. Animals whose
tumors grew to larger than 2000 mm3 were considered to have progressed
and were euthanized. Animals whose tumors became ulcerated prior to pro-
gression or complete response were euthanized and removed from the study.
Tumor Rechallenge Studies
Naive BALB/c mice and mice inoculated previously with CT26 colon carci-
noma cells and treated as described above were inoculated with CT26 cells
into the left (not inoculated previously) unilateral thoracic flank. Where indi-
cated, some mice were also inoculated with 1 3 105 EMT6 breast carcinoma
cells in Matrigel into the fourth mammary fat pad. Where indicated, some mice
were also depleted of CD8+ T cells by injection of 250 mg of CD8-depleting
antibodies 1 day before and 3 days after tumor reinoculation. Tumors were
measured two times per week as described above. Animals whose tumors
became ulcerated/necrotic or whose combined tumor burden exceeded
2,000 mm3 were euthanized.
Viral Infection Studies
For acute infections, C57BL6/J mice were infected intravenously with 23 106
plaque-forming units (pfu) of the Armstrong strain of LCMV. For chronic infec-
tions, C57BL6/J mice, TIGITfl/fl mice, and TIGITfl/fl;CD4cre mice were infected
intravenously with 2 3 106 pfu of the Clone 13 strain of LCMV and treated
with intraperitoneal injections of 500 mg and 250 mg of depleting anti-CD4
antibodies (clone GK1.5) 3 days before and 4 days after infection, respectively.
Where indicated, mice infected with the Clone 13 strain of LCMV were
randomly recruited into experimental groups and treated with intraperitoneal
injections of 200 mg of isotype control antibodies, 200 mg of anti-PD-L1 anti-
bodies, and/or 500 mg of anti-TIGIT antibodies three times per week from
days 28–42 postinfection.
TR-FRET with Transfected Cell Lines
Chinese hamster ovary (CHO) cells were transfected with N terminus SNAP-
tagged (ST) CD226 and N terminus HA-TIGIT and then labeled to measure
TR-FRET either between the SNAP donor and the SNAP acceptor or between
the SNAP acceptor and the anti-HA donor.
TR-FRET with Human T Cells
Human anti-TIGIT (Genentech clone 1F4), anti-CD226 (Santa Cruz Biotech-
nology), and anti-HVEM (eBioscience) were conjugated with fluorophores
compatible with TR-FRET (Cisbio). Primary human T cells were magnetic acti-
vated cell sorting (MACS)-enriched from blood and stimulated in vitro with
plate-bound anti-CD3 and anti-CD28 for 72 hr. TIGIT-expressing and nonex-
pressing T cells (all expressing CD226) were then sorted, rested without stim-
ulation for 72 hr, and restimulated for 48 hr before incubation with FRET
antibodies.CaAnimal Study Oversight
All animal studieswere approved byGenentech’s Institutional Animal Care and
Use Committee. The group sizes used for in vivo studies were those estimated
to be the smallest necessary to generate meaningful data. Studies were not
conducted in a blinded fashion. Mice were monitored regularly, and those
requiring medical attention were provided with appropriate care and excluded
from the studies.
Additional details are provided in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.10.018.
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